Cargando…

NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program

Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general p...

Descripción completa

Detalles Bibliográficos
Autores principales: Maani, Nika, Westergard, Shelley, Yang, Joanna, Scaranelo, Anabel M., Telesca, Stephanie, Thain, Emily, Schachter, Nathan F., McCuaig, Jeanna M., Kim, Raymond H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562659/
https://www.ncbi.nlm.nih.gov/pubmed/31121919
http://dx.doi.org/10.3390/cancers11050707
_version_ 1783426353147674624
author Maani, Nika
Westergard, Shelley
Yang, Joanna
Scaranelo, Anabel M.
Telesca, Stephanie
Thain, Emily
Schachter, Nathan F.
McCuaig, Jeanna M.
Kim, Raymond H.
author_facet Maani, Nika
Westergard, Shelley
Yang, Joanna
Scaranelo, Anabel M.
Telesca, Stephanie
Thain, Emily
Schachter, Nathan F.
McCuaig, Jeanna M.
Kim, Raymond H.
author_sort Maani, Nika
collection PubMed
description Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general population. Impaired emotional functioning is reported as a comorbidity that may influence the participation of NF1 patients in regular clinical surveillance despite their increased risk of breast and other cancers. Despite emphasis on breast cancer surveillance in women with NF1, the uptake and feasibility of high-risk screening programs in this population remains unclear. A retrospective chart review between 2014–2018 of female NF1 patients seen at the Elizabeth Raab Neurofibromatosis Clinic (ERNC) in Ontario was conducted to examine the uptake of high-risk breast cancer screening, radiologic findings, and breast cancer characteristics. 61 women with pathogenic variants in NF1 enrolled in the high-risk Ontario breast screening program (HR-OBSP); 95% completed at least one high-risk breast screening modality, and four were diagnosed with invasive breast cancer. Our findings support the integration of a formal breast screening programs in clinical management of NF1 patients.
format Online
Article
Text
id pubmed-6562659
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65626592019-06-17 NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program Maani, Nika Westergard, Shelley Yang, Joanna Scaranelo, Anabel M. Telesca, Stephanie Thain, Emily Schachter, Nathan F. McCuaig, Jeanna M. Kim, Raymond H. Cancers (Basel) Article Neurofibromatosis Type I (NF1) is caused by variants in neurofibromin (NF1). NF1 predisposes to a variety of benign and malignant tumor types, including breast cancer. Women with NF1 <50 years of age possess an up to five-fold increased risk of developing breast cancer compared with the general population. Impaired emotional functioning is reported as a comorbidity that may influence the participation of NF1 patients in regular clinical surveillance despite their increased risk of breast and other cancers. Despite emphasis on breast cancer surveillance in women with NF1, the uptake and feasibility of high-risk screening programs in this population remains unclear. A retrospective chart review between 2014–2018 of female NF1 patients seen at the Elizabeth Raab Neurofibromatosis Clinic (ERNC) in Ontario was conducted to examine the uptake of high-risk breast cancer screening, radiologic findings, and breast cancer characteristics. 61 women with pathogenic variants in NF1 enrolled in the high-risk Ontario breast screening program (HR-OBSP); 95% completed at least one high-risk breast screening modality, and four were diagnosed with invasive breast cancer. Our findings support the integration of a formal breast screening programs in clinical management of NF1 patients. MDPI 2019-05-22 /pmc/articles/PMC6562659/ /pubmed/31121919 http://dx.doi.org/10.3390/cancers11050707 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Maani, Nika
Westergard, Shelley
Yang, Joanna
Scaranelo, Anabel M.
Telesca, Stephanie
Thain, Emily
Schachter, Nathan F.
McCuaig, Jeanna M.
Kim, Raymond H.
NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
title NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
title_full NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
title_fullStr NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
title_full_unstemmed NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
title_short NF1 Patients Receiving Breast Cancer Screening: Insights from The Ontario High Risk Breast Screening Program
title_sort nf1 patients receiving breast cancer screening: insights from the ontario high risk breast screening program
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562659/
https://www.ncbi.nlm.nih.gov/pubmed/31121919
http://dx.doi.org/10.3390/cancers11050707
work_keys_str_mv AT maaninika nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT westergardshelley nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT yangjoanna nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT scaraneloanabelm nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT telescastephanie nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT thainemily nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT schachternathanf nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT mccuaigjeannam nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram
AT kimraymondh nf1patientsreceivingbreastcancerscreeninginsightsfromtheontariohighriskbreastscreeningprogram